Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. Now, with new data indicating the drug could prolong patients’ lives, the company is ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

Approximately a decade ago, large genomic studies revealed that up to 20% of patients with metastatic prostate cancer carry germline or somatic loss-of-function alterations in HRR genes (BRCA2, BRCA1, ...

CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 that ...

This has to be looked at as a multifactorial issue, says Joseph Renzulli, MD, of Yale School of Medicine, who shares his perspectives on why that's the case. (3:22) Pelvic Lymph Node Dissection: Is It ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...

Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...